Johnson & Johnson Innovative Medicine

At Johnson & Johnson, our work begins and ends with patients. As we look ahead to #AABB2025, we reflect on the stories of Ivy and Ann, two individuals living with warm autoimmune hemolytic anemia (wAIHA), whose courage reminds us why we push for new discoveries. Their experiences highlight the importance of listening closely to patient voices — not just as participants in research, but as partners who help shape and inform advanced solutions. Join us as we continue to reimagine rare autoantibody disease research and transform what care looks like for patients everywhere. Learn more about the critical unmet need in wAIHA: https://lnkd.in/ejMfaMWM

#NEWS: The U.S. FDA has granted Fast Track Designation to our investigational therapy for patients with metastatic castration-resistant prostate cancer (mCRPC), recognizing the urgent need for more effective and/or tolerable options for this challenging disease.  At Johnson & Johnson, we continue to build on our legacy in prostate cancer care by pioneering the next wave of innovation for patients with #ProstateCancer: https://lnkd.in/eDvTFinJ #JNJOncology

Applications for our Global Oncology Summer Internship Program in Clinical Science, Discovery Science, Translational Research, and more are open!    This internship is a hands-on experience in disease biology, innovative drug development, and cutting-edge science. Selected students will work with Johnson & Johnson mentors on their own individual research projects, and be given the opportunity to present these projects to their teams, the Oncology Senior Leadership Team, and at the annual Research Symposium.     Join our global community of scientists-in-training - discover open roles now: https://lnkd.in/gTcjYmz7    #jnj #internships #oncology #clinical #research 

For people living with head and neck cancer, even basic activities like speaking, swallowing and eating can become difficult, and many are unable to receive further treatment after initial therapy. That’s why advancing new treatment options is so critical. At #ESMO25, we’re proud to share the first results from our investigational study in recurrent or metastatic head and neck squamous cell carcinoma – a patient population facing limited treatment options. Building on our lung cancer portfolio, we’re bringing the same scientific expertise to EGFR-driven head and neck cancer, expanding the potential of innovative therapies to more patients with this aggressive disease. Learn how we’re bringing new science forward: https://lnkd.in/eibFn9TB #JNJOncology

#PHridayPHacts: #PulmonaryHypertension (PH) most often affects people between the ages of 30 and 60. It often takes patients years to receive a proper diagnosis, which can delay care and worsen outcomes. As we age, the risk of developing Group 1 PH, known as #PulmonaryArterialHypertension (PAH), increases. #JNJCardiopulmonary

In muscle-invasive #BladderCancer, some patients undergo surgery without the benefit of pre-surgical therapy, a factor that can negatively affect outcomes. At Johnson & Johnson, we’re reimagining drug delivery and exploring new approaches. The latest data presented at #ESMO25 provide important insights that may help inform future treatments for patients. Learn how we’re working to advance care for patients facing this aggressive, life-altering disease : https://lnkd.in/ebtPaK3Y #JNJOncology

Over the last 15 years, oncology has seen remarkable breakthroughs—immunotherapy, CAR T-cell therapies, the advent of precision medicine, DNA sequencing, liquid biopsies and new tools to screen for cancers. But with rapid innovation, comes new challenges. As oncology strategist Alyssa Hulahan-Castellano shared, many clinicians are feeling the pressure of nonstop change. Our Oncology Care Index confirms these struggles. 75% of oncologists find the pace of new treatment development overwhelming, while 70% struggle to navigate the complexities of cancer treatment guidelines. To keep innovation moving forward, oncologists see opportunities in collaboration, AI and broader clinical trial access. Explore more insights from the Oncology Care Index: https://lnkd.in/eyshABXA #JNJOncology #InFrontOfCancer

Rare autoantibody diseases like warm autoimmune hemolytic anemia (wAIHA) place a heavy mental and emotional toll on patients. New research presented at the 2025 #NORDSummit highlights the critical impact of partnering with patients to guide the development of educational resources. At Johnson & Johnson we believe progress is only possible through true partnership and collaboration with patients. Join us as we continue to reimagine rare autoantibody disease research and help shape solutions that can transform care and improve lives for patients everywhere. Learn more about the unmet need in wAIHA: https://bit.ly/3WF0Qou #JNJImmunology

Progress in cancer care is built one discovery at a time. That’s why we’re delivering bold advancements in solid tumor treatment to address some of the most urgent unmet needs for patients worldwide. Our data at the 2025 ESMO - European Society for Medical Oncology Congress showcase the depth of our pipeline and the promise of our innovation. Across lung, bladder, prostate, and head and neck cancer, we’re driving the next wave of transformative therapies for patients: https://bit.ly/4qdr7I4 #JNJOncology #ESMO25

As a company driven by innovation, Johnson & Johnson is actively exploring emerging Artificial Intelligence and Machine Learning (AI/ML) techniques to help advance drug discovery and development. To build on this commitment, we are proud to announce the launch of the Pitching Critical Assessment for Therapeutic Protein Design (CAT-PD) QuickFire Challenge. Innovators worldwide are invited to submit their potentially transformative computational techniques aimed at designing antibody sequences de novo against “hard-to-drug” targets. Apply by November 21 for the opportunity to showcase your models/technologies to Johnson & Johnson Innovative Medicine R&D leadership. https://bit.ly/3W88Myv